stockrow
Saturday 7 November 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.
- EPS
- −45.7%
- Free cash flow
- −23.0%
- Total debt
- −66.7%
Quarter to June 2026, against a year earlier
25.29
0.36
−1.40%
Follow NGNE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.48 | 12.89 | 16.39 | 18.04 | |
Current Ratio |
10.64 | 13.08 | 16.56 | 18.39 | |
Net Debt/EBITDA |
6.23 | 7.40 | 9.87 | 11.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.84 | 0.70 | 0.93 | |
Capex/Depreciation |
(0.74) | (0.59) | (0.45) | 3.18 | |
Interest Coverage |
— | — | (27,530.00) | (23,798.00) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.05) | (1.17) | (0.82) | (0.92) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(1.07) | (1.18) | (0.82) | (0.93) | |
Cash per Share |
9.99 | 10.90 | 12.61 | 12.54 | |
Shareholders Equity per Share |
9.63 | 10.66 | 12.42 | 12.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.63 | 10.66 | 12.42 | 12.54 | |
Free Cash Flow |
(24.11) | (26.40) | (17.56) | (19.63) | |
Working Capital |
207.41 | 227.88 | 255.36 | 255.81 | |
Capital Expenditures |
(0.35) | (0.28) | (0.13) | (0.13) | |
Net Current Asset Value |
201.68 | 221.39 | 248.05 | 248.23 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.68 | 3.87 | 1.64 | 1.61 | |
Average Assets |
270.84 | 289.22 | 312.17 | 225.98 | |
Average Common Equity |
245.19 | 264.79 | 287.63 | 201.48 |
Columns are period end dates · fundamentals updated 26 Oct 2026